Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. In the early 1960s, Ernest A. McCulloch and James E. started several experiments leading to the discovery of stem cells. It was not until much later in 1987 that exosomes were first identified in a mammalian reticulocyte (red blood cell)[1] and not until 2007 that exosome-mediated transfer of mRNAs and microRNAs was identified as a “novel mechanism of genetic exchange between cells.”[2] [Read more…]
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China
Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillment
FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China’s biopharmaceutical and advanced therapy community. Under the agreement, MineBio will distribute RoosterBio’s full platform of research-grade and CliniControlTM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControlTM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay. [Read more…]
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models
TAICHUNG, Feb. 13, 2026 — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells to generate multi-target nanobody-based CAR-T cells. [Read more…]
Advances in Exosome Isolation and Characterization: Technologies, Commercial Vendors, and Clinical Implications
Because exosomes are being explored for a diverse range of therapeutic applications, it is critical to optimize exosome isolation methods for maximum yield, purity, and reproducibility. Beyond the classical ultracentrifugation method, there are now several commercial exosome isolation kits developed around specific principles, such as charge neutralization-based precipitation, gel-filtration, and affinity purification using magnetic beads, that are available in the global market. [Read more…]
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
Singapore, 12 December 2025 – Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 27
- Next Page »